Alprostadil

Author: Prof. Dr. med. Peter Altmeyer

Our authors

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Prostaglandin derivative.

Half-life
This section has been translated automatically.

0,08–0,16 h

Indication
This section has been translated automatically.

Peripheral arterial occlusive disease in stage III and IV, see also arterial occlusive disease, chronic.

Dosage and method of use
This section has been translated automatically.

Gradual dosage starting with 20 μg/day Alprostradil in 50-250 ml NaCl 0.9% slowly over at least 1 hour i.v., increase the dose to max. 60 μg/day.

Notice! In patients with heart failure, coronary heart disease, kidney dysfunction or peripheral oedema, the infusion volume should not exceed 50-100 ml/day!

Undesirable effects
This section has been translated automatically.

Temperature rise, confusion, cerebral seizures, RR drop, tachycardia, arthralgia, flush, sweating, chills, fever, leukopenia, leukocytosis, hyperostosis of the long bones, acute pulmonary edema or heart failure. In the infused extremity: pain, erythema, redness.

Interactions
This section has been translated automatically.

s. Table 1.

Contraindication
This section has been translated automatically.

Pregnancy, lactation, heart failure, cardiac arrhythmia, CHD, 6 months after a heart attack, pulmonary edema, severe COPD, liver disease, acute bleeding.

Preparations
This section has been translated automatically.

Prostavasin, Caverject, Muse, Minprog

Tables
This section has been translated automatically.

Main interactions of Alpostradil

Antihypertensives

RR waste

Anticoagulants

Bleeding tendency ↑

Platelet aggregation inhibitor

Bleeding tendency ↑

Vasodilators

mutual effect ↑

Authors

Last updated on: 29.10.2020